- Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
- Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
- Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
- Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Merck Announces First-Quarter 2024 Financial Results
- Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
- REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
- Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
- European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
- FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
More ▼
Key statistics
As of last trade Merck & Co Inc (MRK:NYQ) traded at 128.05, -3.79% below its 52-week high of 133.10, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 129.20 |
---|---|
High | 129.20 |
Low | 128.03 |
Bid | 128.04 |
Offer | 128.06 |
Previous close | 129.29 |
Average volume | 6.83m |
---|---|
Shares outstanding | 2.53bn |
Free float | 2.53bn |
P/E (TTM) | 146.15 |
Market cap | 330.23bn USD |
EPS (TTM) | 0.8921 USD |
Annual div (ADY) | 3.08 USD |
---|---|
Annual div yield (ADY) | 2.38% |
Div ex-date | Mar 14 2024 |
Div pay-date | Apr 05 2024 |
Data delayed at least 15 minutes, as of May 14 2024 17:17 BST.
More ▼